Increased hippocampal quinone reductase 2 in Alzheimer's disease

Neuroscience Letters

Volumn 502, Issue 1, 2011, Pages 10-12

  Hashimoto, Tetsuya ^a   Nakai, Masami ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Alzheimer's disease; Cognitive function; Hippocampus; QR2

Indexed keywords

QUINONE REDUCTASE 2; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE (PHOSPHATE) DEHYDROGENASE (QUINONE); UNCLASSIFIED DRUG;

AGED; ALZHEIMER DISEASE; AMYGDALOID NUCLEUS; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HIPPOCAMPUS; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL; SUPERIOR FRONTAL GYRUS; WESTERN BLOTTING;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; AMYGDALA; CASE-CONTROL STUDIES; FEMALE; FRONTAL LOBE; HIPPOCAMPUS; HUMANS; MALE; MIDDLE AGED; QUINONE REDUCTASES;

EID: 80051786159     PISSN: 03043940     EISSN: 18727972     Source Type: Journal    
DOI: 10.1016/j.neulet.2011.07.008     Document Type: Article

References (20)

1. Amada N., Aihara K., Ravid R., Horie M. Reduction of NR1 and phosphorylated Ca2+/calmodulin-dependent protein kinase II levels in Alzheimer's disease. Neuroreport 2005, 16:1809-1813.
2. Ansari M.A., Scheff S.W. Oxidative stress in the progression of Alzheimer disease in the frontal cortex. J. Neuropathol. Exp. Neurol. 2010, 69:155-167.
3. Benoit C.E., Bastianetto S., Brouillette J., Tse Y., Boutin J.A., Delagrange P., Wong T., Sarret P., Quirion R. Loss of quinone reductase 2 function selectively facilitates learning behaviors. J. Neurosci. 2010, 30:12690-12700.
4. Braak H., Braak E. Evolution of the neuropathology of Alzheimer's disease. Acta Neurol. Scand. Suppl. 1996, 165:3-12.
5. Brouillette J., Quirion R. Transthyretin: a key gene involved in the maintenance of memory capacities during aging. Neurobiol. Aging 2008, 29:1721-1732.
6. Brunmark A., Cadenas E., Lind C., Segura-Aguilar J., Ernster L. DT-diaphorase-catalyzed two-electron reduction of quinone epoxides. Free Radic. Biol. Med. 1987, 3:181-188.
7. Buryanovskyy L., Fu Y., Boyd M., Ma Y., Hsieh T.C., Wu J.M., Zhang Z. Crystal structure of quinone reductase 2 in complex with resveratrol. Biochemistry 2004, 43:11417-11426.
8. Gella A., Durany N. Oxidative stress in Alzheimer disease. Cell Adhes. Migr. 2009, 3:88-93.
9. Harada S., Fujii C., Hayashi A., Ohkoshi N. An association between idiopathic Parkinson's disease and polymorphisms of phase II detoxification enzymes: glutathione S-transferase M1 and quinone oxidoreductase 1 and 2. Biochem. Biophys. Res. Commun. 2001, 288:887-892.
10. Lind C., Vadi H., Ernster L. Metabolism of benzo(a)pyrene-3,6-quinone and 3-hydroxybenzo(a)pyrene in liver microsomes from 3-methylcholanthrene-treated rats. A possible role of DT-diaphorase in the formation of glucuronyl conjugates. Arch. Biochem. Biophys. 1978, 190:97-108.
11. McKhann G., Drachman D., Folstein M., Katzman R., Price D., Stadlan E.M. Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984, 34:939-944.
12. Mirra S.S., Heyman A., McKeel D., Sumi S.M., Crain B.J., Brownlee L.M., Vogel F.S., Hughes J.P., van Belle G., Berg L. The consortium to establish a registry for Alzheimer's disease (CERAD). Part II: standardization of the neuropathologic assessment of Alzheimer's disease. Neurology 1991, 41:479-486.
13. Morra J.H., Tu Z., Apostolova L.G., Green A.E., Avedissian C., Madsen S.K., Parikshak N., Toga A.W., Jack C.R., Schuff N., Weiner M.W., Thompson P.M. Automated mapping of hippocampal atrophy in 1-year repeat MRI data from 490 subjects with Alzheimer's disease, mild cognitive impairment, and elderly controls. Neuroimage 2009, 45:S3-S15.
14. Nosjean O., Ferro M., Coge F., Beauverger P., Henlin J.M., Lefoulon F., Fauchere J.L., Delagrange P., Canet E., Boutin J.A. Identification of the melatonin-binding site MT3 as the quinone reductase 2. J. Biol. Chem. 2000, 275:31311-31317.
15. Pappolla M.A., Omar R.A., Kim K.S., Robakis N.K. Immunohistochemical evidence of oxidative [corrected] stress in Alzheimer's disease. Am. J. Pathol. 1992, 140:621-628.
16. Schuff N., Woerner N., Boreta L., Kornfield T., Shaw L.M., Trojanowski J.Q., Thompson P.M., Jack C.R., Weiner M.W. MRI of hippocampal volume loss in early Alzheimer's disease in relation to ApoE genotype and biomarkers. Brain 2009, 132:1067-1077.
17. Selkoe D.J. Alzheimer's disease: a central role for amyloid. J. Neuropathol. Exp. Neurol. 1994, 53:438-447.
18. Vella F., Ferry G., Delagrange P., Boutin J.A. NRH:quinone reductase 2: an enzyme of surprises and mysteries. Biochem. Pharmacol. 2005, 71:1-12.
19. Wang W., Le W.D., Pan T., Stringer J.L., Jaiswal A.K. Association of NRH: quinone oxidoreductase 2 gene promoter polymorphism with higher gene expression and increased susceptibility to Parkinson's disease. J. Gerontol. A: Biol. Sci. Med. Sci. 2008, 63:127-134.
20. Wang Y., Santa-Cruz K., DeCarli C., Johnson J.A. NAD(P)H: quinone oxidoreductase activity is increased in hippocampal pyramidal neurons of patients with Alzheimer's disease. Neurobiol. Aging 2000, 21:525-531.